4-(1H-pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine

Synonym
Product Category
Product Code
CAS Number
MDL Number
Pubchem CID
Reaxys RN
INCB032304
API & Intermediates
KUMI0F319
941685-27-4
MFCD11857754
42631346
18703659
image-155171-Trimethyl(trifluoromethyl)silane_reagent.png
Chemical Name
Molecular Formula
Molecular Weight
Assay
Appearance
Melting Point
Packaging
Storage
4-(1H-pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine
C13H10ClN3O2S
307.75
≥98%
White to Brown Solid
 
5g,10g,20g,50g,100g,500g,1kg and 25kg
Store at 2-8 temp.
4-(1H-pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine (aka INCB032304) is a pharmaceutical intermediate that typically used in the preparation of Baricitinib, as a selective orally bioavailable JAK1/JAK2 inhibitor, in the treatment of rheumatoid arthritis (RA).
Enantioselective synthesis of janus kinase inhibitor INCB018424 via an organocatalytic aza-michael reaction. [1]
The pharmacokinetics, pharmacodynamics and safety of baricitinib, an oral JAK ½ inhibitor, in healthy volunteers. [2]
Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. [3]
References:
[1] Q.Lin, et al, Org. Lett., 2009, 11(9), pp 1999-2002.
[2] J.G.Shi, et al, J. Clin. Pharmacol, 2014, 54(12), pp 1354-1361.
[3] L.Yao, et al, J. Med. Chem., 2017, 60(20), pp 8336-8357.
Signal Word
Hazard Statements
Precautionary Statements
HS Code
RIDADR
Legal Information
Warning
H302

2933599590
NONH for all modes of transport

1. Product Specification
Available on request.
2. Safety Data Sheet
Available on request.
Please inquire for pricing and availability of this product by writing email to sales@kumidas.com.